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ABSTRACT (300 max) 1 
Background: Patients with longstanding ulcerative colitis (UC) undergo regular dysplasia surveillance 2 
because of increased colorectal cancer risk. Previous studies demonstrated that autofluorescence 3 
imaging (AFI) and chromoendoscopy (CE) increased dysplasia detection. The aim of this study was to 4 
determine whether AFI should be further studied as an alternative method for dysplasia surveillance 5 
in patients with longstanding UC.    6 
Methods: In this prospective international, randomised trial, 210 patients undergoing colonoscopy 7 
surveillance for longstanding UC were randomised between 1 August 2013 and 10 March 2017 for 8 
inspection with either AFI or CE (105:105). Randomisation was minimised for a previous history of 9 
dysplasia and a previous history of primary sclerosing cholangitis. The main outcome was the relative 10 
dysplasia detection rate calculated by the ratio of AFI versus CE. This relative dysplasia detection rate 11 
was determined for the proportion of UC patients in which at least one dysplastic lesion was 12 
detected and for the mean number of dysplastic lesions per patient. The relative dysplasia detection 13 
rate needed to be above 0·67 for both outcomes to support performing a subsequent large non-14 
inferiority trial, using an 80% confidence interval. Analysis was performed per protocol. The trial is 15 
registered at Netherlands Trial Register (NTR4062). 16 
Findings: AFI detected dysplasia in 13 (12·4%) patients, compared to 20 patients (19·1%) with CE. The 17 
relative dysplasia detection rate of CE versus AFI for the proportion of UC patients with at least one 18 
dysplastic lesion was 0·65 (80% CI; 0·43-0·99). The mean number of detected dysplastic lesions per 19 
patient was 0·13 for AFI compared to 0·37 for CE (relative dysplasia detection rate 0·36, 80% CI; 0·21-20 
0·61).  Two patients experienced an adverse event (intraprocedural mild bleeding = 1, abdominal 21 
pain = 1) in the AFI-arm and three patients (intraprocedural mild bleeding = 2, perforation = 1) in the 22 
CE-arm.  23 
Interpretation: In this randomised study comparing AFI with CE for dysplasia surveillance in patients 24 
with longstanding UC, AFI did not meet criteria for proceeding to a large non-inferiority trial. 25 
Therefore, current AFI technology should not be further investigated as an alternative dysplasia 26 
surveillance method. 27 
Funding: Olympus Europe and Olympus Keymed, Oxford and Nottingham NIHR biomedical research 28 
centres. 29 
 30 
31 
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RESEARCH IN CONTEXT 1 
Evidence before this study 2 
Patients with longstanding ulcerative colitis are at increased risk for developing colorectal cancer. To 3 
detect cancer and dysplasia at an early stage, periodic colonoscopic surveillance is recommended. 4 
Chromoendoscopy, in which the application of topical dye is used to highlight subtle mucosal 5 
changes, is currently advised in guidelines for performing dysplasia surveillance. However, 6 
chromoendoscopy is poorly adopted because it is time-consuming and laborious. We searched 7 
PubMed using Mesh-terms “ulcerative colitis”, “autofluorescence imaging” and “dysplasia”. We 8 
found one prospective, randomised back-to-back colonoscopy trial in 50 patients with longstanding 9 
ulcerative colitis which compared miss-rates of autofluorescence imaging compared with standard 10 
white light endoscopy. This study reported a 50% miss rate of white light endoscopy and 0% miss 11 
rate of autofluorescence imaging. 12 
Added value of this study 13 
This is the first study to assess a direct head-to-head comparison of autofluorescence imaging versus 14 
chromoendoscopy for dysplasia detection in patients with longstanding ulcerative colitis. This study 15 
was designed to determine whether autofluorescence imaging should be further studied as a 16 
dysplasia surveillance method that is non-inferior to chromoendoscopy. Our data demonstrate that, 17 
autofluorescence imaging did not meet predefined endpoints, and should not be further studied as 18 
an alternative dysplasia surveillance method.  In a post hoc analysis chromoendoscopy was superior 19 
for number of dysplastic lesions detected. 20 
Implications of all the available evidence 21 
This study contributes to the growing body of evidence that chromoendoscopy is the preferred 22 
method for performing dysplasia surveillance in patients with longstanding ulcerative colitis. Further 23 
efforts should be undertaken to improve adoption of chromoendoscopy in current daily practice. 24 
Additional long-term studies are needed to determine whether increased dysplasia detection results 25 
in reduced CRC incidence and mortality. 26 
 27 
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INTRODUCTION  1 
Patients with longstanding ulcerative colitis (UC) are at increased risk of developing 2 
colorectal cancer (CRC).1 The risk of cancer is 2·4 times higher in UC patients compared to the general 3 
population, rising to 4·8 times in those with extensive colitis,1 and the risk of cancer-related death is 4 
1·6 times higher.2 As cancer develops from normal mucosa to low- and high-grade dysplasia, early 5 
detection and intervention could halt this process. Multiple practice guidelines therefore recommend 6 
that patients with longstanding extensive or left-sided colitis should undergo surveillance at set 7 
intervals depending on individual risk factors.3-5 The gain of colonoscopic surveillance has recently 8 
been demonstrated in both colorectal cancer development and CRC-related mortality, the latter 9 
probably due to cancers being detected at an earlier stage when compared to no surveillance.6 It is 10 
logical that these early stage cancers also have a more favorable prognosis, leading to improved 11 
survival. Although colonoscopic surveillance is effective in terms of reducing morbidity and mortality, 12 
a significant proportion of CRCs detected in these patients are post-colonoscopy CRCs.7,8 This finding 13 
suggests accelerated carcinogenesis or ineffective surveillance where dysplastic lesions may be 14 
missed during surveillance colonoscopies.               15 
The optimal method of surveillance has been the focus of several studies. In the recent 16 
published SCENIC consensus statement, all currently available evidence regarding dysplasia 17 
surveillance was summarised.9 This statement used rigorous methodology for meta-analyses and 18 
development of recommendations. The conclusion of the available evidence was that 19 
chromoendoscopy (CE) performed with high-definition endoscopic systems was the preferred 20 
method for dysplasia surveillance. As dysplasia in patients with UC tends to be flat and indistinct,10,11 21 
using CE for surveillance highlights subtle mucosal differences and thereby enhances dysplasia 22 
detection.12 Although CE facilitates improved dysplasia detection rates and is widely recommended 23 
as surveillance strategy in current guidelines, it has not yet been completely adopted into daily 24 
endoscopy practice.13 Explanations for this poor adoption include the long learning curve associated 25 
with CE, longer procedural times and skepticism whether CE improves clinically relevant outcomes 26 
such as CRC incidence and mortality in patients with longstanding UC.14 Therefore, alternative 27 
surveillance methods are being investigated which might be more straightforward, in order to 28 
improve detection rates and adherence to current surveillance guidelines.15-17  29 
Autofluorescence imaging (AFI) is an imaging technique that has been developed to improve 30 
detection of dysplastic lesions.18 AFI is an advanced imaging technique during which blue light is used 31 
to illuminate the mucosa. Endogenous tissue fluorophores e.g. collagen are excited by blue light and 32 
subsequently emit fluorescent light at a longer wavelength.18 The intensity of the autofluorescent 33 
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light emitted differs between neoplastic and normal colonic tissue.19 The endoscopic system 1 
processes the autofluorescent light into a real time pseudo-colour image on the screen. With AFI, 2 
neoplastic lesions are seen as purple and non-neoplastic mucosa appears green, thereby increasing 3 
the contrast between neoplastic and non-neoplastic mucosa. This push-button technology does not 4 
require additional dyes or catheters and is less likely to prolong procedure time than CE. It may also 5 
be simpler to interpret the images generated to show dysplasia with a simple colour change; 6 
however the resolution and image stability is less good than standard high definition white light and 7 
endoscopists are highly reliant on the technology to red flag dysplasia. 8 
Both AFI and CE have been shown to be superior to white light endoscopy in dysplasia 9 
detection in patients with longstanding UC,12,20 but have never been investigated in a head-to-head 10 
comparison. The hypothesis for the “chromoendoscopy versus autoFluorescence Imaging for 11 
Neoplasia Detection in patients with longstanding Ulcerative Colitis” (FIND-UC) randomised 12 
controlled trial is that CE and AFI are equally effective for the detection of dysplastic lesions in 13 
patients undergoing colonoscopic surveillance for UC. Performing a formal non-inferiority trial would 14 
require over 1,000 participants. Therefore we decided to perform a phase II pathfinder study with 15 
predefined performance thresholds. The primary outcome was dysplasia detection, and the focus of 16 
this study was on investigating whether AFI could meet clinical criteria to go forward to an 17 
appropriately powered study versus CE. 18 
19 
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METHODS  1 
Study Design and Setting 2 
This prospective, parallel randomised international trial compared dysplasia detection rates 3 
of AFI against CE in an UC-dysplasia surveillance cohort in 5 centres in the Netherlands and the UK. 4 
The study is reported in accordance with the CONSORT statement for reporting randomised 5 
controlled trials.21   6 
 7 
Patients 8 
Consecutive eligible patients undergoing dysplasia surveillance for longstanding UC were 9 
approached for inclusion in this trial. Patients were considered eligible who were aged 18 years or 10 
older and had been diagnosed with extensive colitis (Montreal E3) at least 8 years ago or left-sided 11 
colitis (Montreal E2) at least 15 years ago. Exclusion criteria included a change in bowel habit in the 12 
preceding two months under maintenance therapy, prior colonic resection, presence of severe 13 
comorbidity, proven genetic predisposition for CRC, coagulopathy or use of an anticoagulant drug 14 
precluding taking biopsies, and those with known colonic neoplasia (referred patients or patients 15 
refusing endoscopic or surgical treatment). Discontinuation criteria after consent included active 16 
colitis (defined as partial endoscopic Mayo score ≥222) and poor bowel preparation (scoring <6 points 17 
on the Boston Bowel Preparation Scale23). All patients were prepared with osmotic laxatives 18 
according to the local hospital protocol. 19 
 20 
Endoscopists, Clinical Teaching Session and Endoscopy Equipment 21 
At each participating center, 2 endoscopists performed colonoscopies for inclusion in this 22 
study. These endoscopists had extensive experience (>500 colonoscopies) as well as experience in 23 
performing dysplasia surveillance colonoscopies in patients with longstanding UC using CE. At the 24 
start of the study, participating endoscopists were required to have performed at least 20 25 
procedures with the AFI study equipment in patients with longstanding UC. We presumed that this 26 
resulted in comparable scope-handling abilities and interpretation of the endoscopic images 27 
between endoscopists when using AFI. 28 
Prior to the start of the study, all participating endoscopists were invited for a one-day 29 
clinical teaching session at the Academic Medical Center, Amsterdam, the Netherlands. During this 30 
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session a standardised teaching module was delivered and a hands-on colonoscopy demonstration 1 
was performed. In this standardised teaching module both lesion detection with AFI and CE were 2 
discussed in detail. The teaching included 40 still images of AFI and corresponding HD-WLE images. 3 
Both arms used CFH240AZL/I colonoscopes and Lucera Elite video processor system 4 
(Olympus Medical Systems Co., Tokyo, Japan). High-definition monitor output was used for both 5 
arms placed at appropriate viewing distances at the discretion of the endoscopist. 6 
 7 
Randomisation and allocation concealment 8 
 Patients were allocated by an online randomisation program (ALEA; 9 
http//www.tenalea.com/) by a research assistant to undergo colonoscopy with either AFI or CE (1:1 10 
ratio). Patients with no inflammatory signs and acceptable bowel preparation were randomised 11 
when the caecum was reached prior to start of withdrawal. Minimisation was performed for previous 12 
personal history of histological proven dysplasia and personal history of concomitant primary 13 
sclerosing cholangitis (PSC). Both variables are associated with an increased risk of developing future 14 
dysplasia.3-5 All study centers had access to this randomisation program. 15 
 The executing endoscopists could not be blinded for the endoscopic strategy used (AFI or CE) 16 
as the two strategies are highly different in the images generated. As colonic tissue from patients in 17 
the CE arm contained blue dye in the specimen, the pathologists might also not be blinded. 18 
 19 
Procedure 20 
The procedures were performed under conscious sedation using intravenous 21 
benzodiazepines and opiates when requested. Carbon dioxide insufflation was used for all 22 
colonoscopies. The endoscope was advanced to the caecum with the endoscope set in the high-23 
definition white light endoscopy (HD-WLE) mode. Caecal intubation was confirmed by identification 24 
of the appendiceal orifice and ileocaecal valve or by intubation of the ileum. Upon reaching the 25 
cecum, the level of bowel preparation was determined according to the Boston Bowel Preparation 26 
Score (BBPS).23 In case the BBPS was <6 or the patient had active colitis, the endoscope was 27 
withdrawn in the HD-WLE mode and the patient was excluded from the study. If the bowel 28 
preparation was sufficient and there was no active inflammation, the patient underwent 29 
colonoscopy according to the study protocol. At the start of withdrawal, 20 mg hyoscine 30 
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butylbromide (Buscopan, Bohringer Ingelheim) was given intravenously at the discretion of the 1 
endoscopist to reduce colonic motility. 2 
 When the patient was allocated to AFI on entering the cecum, the imaging mode was directly 3 
switched to AFI for scrutinizing the entire colon for the presence of suspicious areas, mucosal 4 
irregularities, unusual ulcers and strictures during inspection on withdrawal. In the CE arm, each 5 
segmental part of the colon was sprayed with 0.1% methylene blue solution or 0.2% indigocarmine 6 
solution using a dye-spray catheter in a segmental manner on withdrawal of the endoscope, excess 7 
of dye was suctioned and each colonic segment was scrutinised in the HD-WLE mode. 8 
All suspicious areas were classified according to the Paris classification.24 The size in 9 
millimetres and segment of the colon was recorded. For all detected lesions, their location with 10 
respect to the extent of colitis (proximal to or within the inflammatory changed colon on endoscopy) 11 
was noted. Digital still images of all detected lesions and their adjacent mucosa were taken. 12 
Subsequently, all detected lesions and their adjacent ‘normal’ mucosa were sampled for 13 
histopathological evaluation. In case of obvious hyperplastic or inflammatory lesions, histopathology 14 
was performed for a maximum of three of these lesions. Two random biopsy specimens were taken 15 
from every bowel segment to document the presence of histologic inflammation or invisible 16 
dysplasia.  17 
Research personnel attending the endoscopy recorded all procedural findings on a 18 
predesigned case record form and used a stopwatch to time the total colonoscopy and withdrawal 19 
times. The stopwatch was paused for bowel cleansing, lesion removal, and dye-spray application and 20 
this time was calculated as the difference between the withdrawal time and the inspection time. 21 
 22 
Histopathology 23 
Histological samples were processed per participating center using standard procedures and 24 
evaluated by a gastrointestinal specialist pathologist. Biopsies were graded in accordance with the 25 
Vienna criteria of gastrointestinal neoplasia and dysplasia consisted of adenomacarcinoma, high-26 
grade dysplasia or low-grade dysplasia. Biopsies demonstrating any grade of dysplasia were reviewed 27 
by a second gastrointestinal specialist pathologist to confirm the initial diagnosis. In total, 10% of 28 
representative samples were double reported as part of internal control. Both dysplastic lesions and 29 
SSLs were considered neoplastic for secondary analysis. Indefinite for dysplasia was considered 30 
neither dysplastic nor neoplastic. The histological diagnosis of all biopsies was used as the reference 31 
 11 
 
standard diagnosis in each patient. Any histopathology slides or samples transferred for external 1 
review had all identifiable data removed except for the unique study number.  2 
 3 
Study outcomes 4 
 The primary study outcome was the relative dysplasia detection rate of dysplasia by AFI 5 
versus CE. This relative dysplasia detection rate was calculated for two co-primary outcome measure; 6 
(1) the proportion of UC patients in which at least one histological proven dysplastic lesion was 7 
detected and (2) the mean number of histological proven dysplastic lesions per patient. If AFI did not 8 
achieve a relative dysplasia detection rate above 0·67 for either co-primary outcome measure, 9 
criteria for proceeding to a larger non-inferiority study were not fulfilled. 10 
Secondary end points included the proportion of patients with at least one neoplastic lesion 11 
and sessile serrated lesion (SSL), the mean number of neoplastic lesions and SSLs, total procedure 12 
and colonoscope withdrawal times, the yield of dysplasia on targeted tissue acquisition versus 13 
random non-targeted biopsies, description of detected lesions and procedure-related complications. 14 
The diagnostic test accuracies of endoscopic prediction of dysplasia of AFI and CE, and analysis of 15 
endoscopic features predicting dysplasia were not reported as these were beyond the scope of the 16 
current manuscript.  17 
 18 
Determination of valuable clinical endpoints and calculation of sample size 19 
The main outcome was the relative dysplasia detection rate calculated by the quotient of CE 20 
over AFI. Although there were two co-primary outcomes, the sample size was based on the binary 21 
outcome (dysplasia yes/no) as this was the outcome likely to provide less statistical power. After 22 
discussion with contributing authors, we determined that AFI would be clinically non-inferior to CE if 23 
its dysplasia detection rate would be within 33% of the dysplasia detection of CE. The non-inferiority 24 
margin of 33% was based on expert opinion of clinicians taking part in this study who all have 25 
experience of clinical trials of endoscopic techniques to increase dysplasia detection and serve on 26 
national committees related to endoscopy. The margin therefore likely reflects the differences 27 
clinicians would be prepared to tolerate before one technique was sufficiently inferior that the wider 28 
endoscopic community would not support a large non-inferiority trial. The chosen non-inferiority 29 
margin of 33% would result in a relative dysplasia detection rate of AFI against CE of at least 0·67 30 
calculated for the two co-primary endpoints. If both relative dysplasia detection rates were 0·67 or 31 
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higher, AFI would be taken forward to an appropriately powered non-inferiority study. If AFI would 1 
perform below this relative dysplasia detection rate of 0·67 for one of two co-primary endpoints, this 2 
would represent a clinically important difference between groups representing a sufficiently large 3 
difference. In this case, it would be decided not to proceed with a full non-inferiority study.    4 
The relative detection rate was used to determine the sample size analysis and was based on the 5 
proportion of patients with longstanding UC in which at least one dysplastic lesion was detected. 6 
Previous studies have found a per patient dysplasia detection rate of 20% when CE was used.25 If AFI 7 
would detect 33% less patients with at least one dysplastic lesion than CE, this would correspond to a 8 
dysplasia detection rate of AFI of 13·3%. The sample size was based on calculating a confidence 9 
interval that would not cross the point of no difference (i.e. a relative difference of 1), if the relative 10 
difference was exactly as hypothesized (e.g. relative detection rate of 0.67) with an 80% confidence 11 
level. It is calculated that 105 patients per arm were required for the study. With this sample size, if 12 
the relative dysplasia detection rate was 0·67, an 80% two-sided confidence interval would range 13 
from 0·44 and 1·00. Calculation of sample size was performed using nQuery Advisor version 7.0 14 
(Statistical Solutions, Cork, Ireland).” 15 
 16 
Statistical methods 17 
The primary outcome was the relative detection rate related to dysplasia detection. The 18 
relative dysplasia detection rate was expressed as a ratio of AFI against CE, along with corresponding 19 
two-sided 80% confidence intervals (CIs). The first co-primary outcome for calculation of the relative 20 
detection rate was any dysplastic lesion per patient (yes/no), whilst the second, related, co-primary 21 
outcome was the number of dysplastic lesions per patient. The analysis of the co-primary outcomes 22 
were performed on a superiority basis, examining the difference between AFI and CE. The Chi-square 23 
test was used for the analysis of dysplasia detection, with confidence intervals for the relative 24 
difference based on the standard error of the log relative risk. For the number of dysplastic lesions, 25 
the data was assumed to follow the negative binomial distribution, as it did not fit the Poisson 26 
distribution well due to overdispersion (i.e. the variance was much greater than the mean), and 27 
negative binomial regression was used to compare between groups. This approach was a change 28 
from that described in the protocol, as it was felt to be a more appropriate method of analysis 29 
(supplementary material 1). For both co-primary outcomes, a 20% significance level was assumed 30 
due to the specific nature of the study. Sensitivity analyses for the primary outcomes were 31 
performed to adjust for the two factors used in the minimisation; previous dysplasia and PSC. For 32 
dysplasia detection this was performed using a generalised linear model assuming a binomial 33 
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distribution and a log link function. This was used in order to obtain the relative detection rate. For 1 
number of dysplastic lesions, negative binomial regression was again used.  2 
Secondary outcomes were the detection and number of neoplastic lesions, detection and 3 
number of SSLs, and also similar outcomes relating to targeted biopsies. These were also analysed on 4 
a per patient basis in an equivalent way to the primary and co-primary outcomes. An additional 5 
outcome was the dysplasia yield for targeted biopsies (excluding obvious hyperplastic and 6 
inflammatory polyps), which was analysed as polyp level variable. To account for the repeat 7 
measurements from the same patients, the analysis was performed using multilevel logistic 8 
regression. A two-level model was used with polyps nested within patients. A final secondary 9 
outcome, withdrawal time, was analysed using the Mann-Whitney test due to skewed distribution of 10 
the outcome. 11 
Analyses were performed with Stata version 13.1 (StataCorp LP., College Station, Texas, USA).  12 
 13 
Ethical Approval and Role of the Funding Source 14 
 All sites received ethical approval from local institutional review boards (AMC2012_366, UK 15 
Research Ethic Committee Reference 13/SC/0369) and all patients gave written informed consent. 16 
Olympus Europe, Hamburg, Germany provided an unrestricted research grant that partially 17 
supported a research fellow to help executing the study. Olympus Keymed UK provided an 18 
unrestricted research grant to support study coordinators at each of the UK study sites. The sponsor 19 
had no role in the trial design, execution, data analysis, interpretation, decision to submit the paper, 20 
or manuscript preparation. JLV, JEE and ED had access to all the study data and all authors reviewed 21 
and approved the final manuscript.  22 
 23 
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RESULTS  1 
 2 
Between 1 August 2013 and 10 March 2017, 407 patients were assessed for eligibility and 3 
251 fulfilled the inclusion criteria and gave informed consent before the trial was completed. Eleven 4 
patients were excluded prior randomisation because of poor bowel preparation (BBPS <6) and 24 5 
patients because of active inflammation (Mayo score ≥2). A total of 210 patients were randomised to 6 
undergo inspection with either AFI or CE (flowchart 1). All 210 patients, 105 in each arm, completed 7 
the study protocol and were available for analysis. Five participants experienced complications as 8 
intraprocedural bleeding after polypectomy (N = 3), a submucosal tear due to manipulation with 9 
biopsy forceps (N = 1) and post-procedural abdominal pain (N = 1) and this did not differ between AFI 10 
and CE. Three of these patients were treated directly with clip placement.  11 
The baseline characteristics for patients who completed the trial were similar (table 1). The 12 
mean age of all participants was 56·1 years (SD 12·7), 41·9% were female and the median UC disease 13 
duration was 21·0 years (IQR 14·5-30·0). The median time since previous surveillance colonoscopy 14 
was 3 years (IQR 1-4). Characteristics of the study procedures are shown in table 2.  15 
In total, 52 dysplastic lesions were identified in 34 patients. The overall dysplasia detection 16 
rate was 16·2% (95% CI, 11·8-21·8). Using CE, an 8mm flat depressed submucosal adenocarcinoma 17 
was detected (Paris classification IIa + IIc, supplemental material 2) and this patient was referred for 18 
subtotal colectomy. Two dysplastic lesions were detected by random biopsies. All other patients with 19 
dysplastic lesions were successfully treated endoscopically except for the patient with 2 invisible 20 
dysplastic lesions found on random biopsies.    21 
 22 
Primary study outcomes  23 
The per-protocol analysis for the main outcomes are summarised in table 3. Binary variables 24 
are summarised by the percentage occurrence in each group, along with the figures on which these 25 
were based. Continuous outcomes are summarised by the mean and standard deviation. For all 26 
outcomes the ratio of values in the AFI group relative to the CE group are presented, along with a 27 
two-sided 80% confidence interval. P-values from the exploratory analyses are also presented.  28 
The results for the primary outcomes relating to dysplastic lesions suggested that AFI 29 
performed less well than CE and did not meet the criteria for proceeding to a larger non-inferiority 30 
study of a relative dysplasia detection rate above 0·67 for either primary outcome measure. Using 31 
CE, dysplasia was detected in 20 (19·1%) patients, while 14 patients (12·4%) were diagnosed with 32 
 15 
 
dysplasia during AFI resulting in a ratio of 0·65 (80% CI 0·43-0·99). More dysplastic lesions per patient 1 
were detected in the CE group than in the AFI group, with a mean of 0·37 (SD ± 1·02) per patient in 2 
the CE group, compared to 0·13 (SD ± 0·37) in the AFI group, relative dysplasia detection rate of 0·36 3 
(80% CI 0·21-0·61), which was statistically significant (p=0·01) in an exploratory superiority analysis. 4 
There was no significant difference between groups when it came to the proportion of patients with 5 
one or more dysplastic lesions. Results from sensitivity analysis resulted in similar outcomes and are 6 
shown in supplementary material 3. Figure 1 shows a low-grade dysplastic lesion photographed with 7 
AFI (1a) and corresponding narrow band imaging (1b) and white light images (1c and 1d). 8 
   9 
Secondary study outcomes 10 
 The analysis of the secondary outcomes suggested that AFI was not non-inferior to CE for all 11 
outcomes; neoplastic lesions, SSLs, targeted biopsies and dysplasia yield. Additionally, the 12 
exploratory analyses suggested significantly better outcomes for CE for the number of neoplastic 13 
lesions, number of targeted biopsies and patient with one or more targeted biopsies. Furthermore, 14 
there was a suggestion that CE was superior for patients with one or more neoplastic lesion and for 15 
presence and number of SSLs, although these results did not quite reach statistical significance. 16 
 An additional secondary outcome, withdrawal time, was examined on a superiority basis. 17 
Total withdrawal times were significantly shorter with AFI (18·0 min, IQR 15·0-24·9) compared to 18 
withdrawal with CE (25·1 min, IQR 18·9-33·8, p<0·0001). This was mainly because of prolonged 19 
procedural time associated with spraying of dye, suctioning of excess dye and taking targeted 20 
biopsies (table 2).   21 
In total, 138 targeted biopsies were taken during extubation with CE and 65 during 22 
extubation with AFI when not taking obvious hyperplastic and inflammatory polyps into account. 23 
During CE, the proportion of patients in whom targeted biopsies were taken was significantly higher 24 
than when extubation was performed with AFI (63·8% vs. 41·9%, p=0·002). The dysplasia yield of 25 
targeted biopsies, excluding obvious hyperplastic and inflammatory polyps did not differ between AFI 26 
and CE (20·0% vs. 26·8%, p=0·29). 27 
 The additional per-biopsy yield of 2,016 collected random biopsies was 0·1% (95% CI, 0-0·4) 28 
and both of these were detected in one patient who already had a visible dysplastic lesion on AFI. 29 
Calculated per patient, there was no additional yield for random biopsies in detecting patients with 30 
dysplasia. 31 
 16 
 
 1 
Characteristics of detected lesions 2 
 Extubation with AFI detected 14 dysplastic lesions while inspection with CE resulted in 38 3 
detected dysplastic lesions. Most dysplastic lesions were located proximal to the descending colon 4 
(table 4). In two (2·6%) of 78 lesions where the surrounding mucosa was biopsied, dysplasia was 5 
detected. In addition to these dysplastic lesions, 151 non-dysplastic lesions were detected by 6 
targeted biopsies in both arms. Three lesions were histologically diagnosed as indefinite for dysplasia 7 
and 1 neuro-endocrine tumour grade 1 was detected.  8 
 Furthermore, 18 SSLs were diagnosed at histopathology. Of these, 13 (72%) were located 9 
proximal to the splenic flexure, and their median size was 8mm (range 2-30). Fifteen (83%) of 18 SSLs 10 
were located in a (previously) inflamed segment. The majority of SSLs (67%) had flat (Paris IIa) 11 
morphology. Eleven SSLs were removed completely, while the others were biopsied only. None of 12 
these SSLs contained dysplasia at histological analysis. In 1 (10%) of 10 patients diagnosed with SSL, a 13 
synchronous dysplastic lesion was detected.   14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
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DISCUSSION 1 
This randomised trial with predefined performance thresholds aimed to investigate non-2 
inferiority of AFI compared to CE for dysplasia detection in patients with longstanding UC. Based on 3 
the relative detection rate of AFI versus CE for the proportion of patients with at least one dysplastic 4 
lesion and the mean number of dysplastic lesions detected per patient, AFI did not meet diagnostic 5 
criteria to be taken forward to an appropriately powered non-inferiority study. Exploratory analysis 6 
showed that CE detected significantly more dysplastic and neoplastic lesions per patient. 7 
Furthermore, using CE during extubation increased the proportion of patients with targeted biopsies 8 
at the cost of prolonged procedural times. Based on our predefined thresholds, we suggest current 9 
AFI technology should not be further studied as alternative to CE, and CE remains the preferred 10 
method for performing dysplasia surveillance in patients with longstanding UC.    11 
Although a previous study showed a decrease in miss rates using AFI compared to WLE, 12 
results could not be corroborated in this head-to-head comparison to CE.20 Using AFI, dysplastic 13 
tissue is visible as purple against a green background of normal colonic tissue. However, two previous 14 
retrospective studies showed that a purple lesion was observed in 38-86% of dysplastic lesions, 15 
possibly indicating that purple AFI color may not lead to detection of all dysplastic lesions in patients 16 
with longstanding UC.26,27 Possibly, those dysplastic lesions that were green on AFI were missed. 17 
Other push-button image-enhanced endoscopy technologies such as narrow band imaging (NBI) have 18 
been formally studied in dysplasia surveillance in IBD patients, without documenting a benefit of NBI 19 
over WLE or CE. 9,20,25,28,29 In a recently published trial performed by Bisschops et al. NBI and CE were 20 
similar in dysplasia detection.30 However, this study was powered to detect a threefold detection 21 
capacity of either technique relative to the other technique thereby precluding any conclusions on 22 
non-inferiority of NBI compared to CE. A recent study comparing I-SCAN to CE and HD-WLE in colitis 23 
did not show a difference in detection between the techniques.31 We are not aware of any other 24 
data available for I-SCAN or Flexible spectral Imaging Color Enhancement (FICE) in colitis. Future 25 
studies proving non-inferiority of new-generation image-enhanced endoscopy techniques may be of 26 
interest. A study primarily looking at implementation suggested a benefit of high definition CE over 27 
HD-WLE. 32 As HD-WLE remains an attractive alternative to high-definition CE several randomized 28 
trials are currently comparing these modalities and the results are awaited.33,34   29 
In this study, CE resulted in more targeted biopsies on average and on a per patient basis. 30 
The per biopsy yield of these targeted biopsies did not differ between AFI and CE (20·0% versus 31 
26·8%, p=0·29). Furthermore, random biopsies did not prove to be beneficial for detecting additional 32 
patients with invisible dysplasia compared to targeted biopsies. In this study, only 2 random biopsies 33 
 18 
 
contained invisible dysplasia. The per-biopsy yield was only 0·1% (95% CI, 0-0·4). A recent published 1 
prospective study in 1,000 IBD patients found that over 30,000 random biopsies yielded a 0·2% per-2 
biopsy rate when performing CE during extubation.35 However, random biopsies did increase the per-3 
patient dysplasia detection rate by 12·8%. Dysplasia detected by random biopsies was associated 4 
with presence of PSC, previous dysplasia and a tubular shortened colon. In a randomised, multicentre 5 
study, 246 patients underwent either targeted plus random biopsies or targeted biopsies alone.36 The 6 
targeted biopsies group was equally high in yield of dysplasia compared to random and targeted 7 
biopsy group. The targeted biopsy approach appeared to be more cost-effective. In line with recent 8 
guidelines4,5, random biopsies may be omitted because of their low yield when performing 9 
surveillance with CE, although specific risk-groups may benefit from this approach, such as those with 10 
PSC.35 11 
In this study, a non-significant trend was observed favoring CE for SSL detection. The majority 12 
of colitis associated cancers may develop from an inflammation-related cancer pathway and the 13 
traditional adenoma-carcinoma pathway.37 Very little is known on the role of the serrated neoplasia 14 
pathway in patients with longstanding UC. Studies on SSL incidence in colitis patients are scarce, and 15 
may be unreliable due to underreporting of serrated lesions as these where considered having no 16 
malignant potential in colitis. In addition, these may have been hard to identify during colonoscopy 17 
due to background inflammation, and their similar endoscopic appearance to post-inflammatory 18 
changes. Previous translational work has shown that a minority of cancers in colitis are related to the 19 
serrated neoplasia pathway.38,39 Whether SSLs are sporadic bystanders or related to ongoing 20 
inflammation is unknown. Interestingly, the majority of SSLs (83%) detected in this study were 21 
located in a (previously) inflamed segment. Previous work also suggests that the synchronous and 22 
metachronous dysplasia risk in patients with SSLs or serrated epithelial changes may be higher.40-42 23 
As published results are scarce, limited by small samples and outcomes are heterogeneous, we 24 
advise to completely remove SSLs in colitis patients whenever possible.        25 
This trial was designed as a phase II pathfinder trial with 210 patients, but proved to be a 26 
challenging trial in terms of recruitment as 407 patients were assessed for eligibility. This was in part 27 
due to our very strict in- and exclusion criteria and the nature of the underlying disease as a 28 
considerable fraction of patients was excluded at the time of colonoscopy because of active Mayo 2 29 
inflammation (N=24) in a bowel segment or poor preparation (N=11). It has been shown previously 30 
that patients undergoing dysplasia surveillance in IBD have less good adherence to bowel 31 
preparation.43 Conducting the very large studies that would be needed to show a benefit of CE in 32 
terms of colorectal cancer prevention are likely to represent a formidable logistical challenge. 33 
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Although multiple studies and practice guidelines clearly support the use of CE for dysplasia 1 
surveillance in patients with longstanding UC, adoption of this technique in daily clinical practice 2 
remains challenging.44 As CE is associated with a long learning curve, training tools should be 3 
developed to promote ongoing learning and improvement of dysplasia detection. Development of 4 
image- and video-libraries, online quizzes and hands-on training days may facilitate learning curves. 5 
Furthermore, prospective longitudinal studies with registration of post-colonoscopy CRCs, morbidity 6 
and mortality are needed to defend against skepticism about using CE for dysplasia surveillance. In 7 
this light, evaluation of findings at follow-up surveillance colonoscopy of FIND-UC participants and 8 
their rates of dysplasia may be of further interest to underline current conclusions and potential 9 
benefit of CE over AFI. Last, as CE has been shown to increase procedural times, redefining 10 
reimbursement payments for performing CE may increase its adoption into clinical practice.  11 
This study has a number of limitations. Three of the five centres were tertiary academic 12 
centres, so the patient populations may not be completely representative of the wider IBD 13 
surveillance population. This is indicated by the high rates of patients with previous dysplasia and 14 
PSC, and the high overall dysplasia detection rate compared to recently published large population 15 
based cohorts of chromoendoscopy in IBD.35,45,46 Most endoscopists were also sub-specialists with 16 
extensive experience in performing CE, and were not blinded which may have led to unconscious bias 17 
and may have favored CE. In common with most trials of CE we did not control for the “washing” 18 
effect of dye-spray which may have improved mucosal visualization, although overall inspection 19 
times were similar. Furthermore, AFI did not meet the predefined clinical acceptability thresholds, 20 
and CE was superior to AFI for the mean number of detected dysplastic lesions per patient. The 21 
dysplasia detection rate per patient of AFI (12·4%) in the FIND-UC trial was at least similar compared 22 
to that of recently published WLE dysplasia detection rates in academic centers.28,35,46 Moreover, 23 
detected dysplastic lesions were predominantly diminutive in size and whether the size of dysplastic 24 
lesions is of clinical importance remains to be addressed. Therefore, we do not think that patients 25 
that were allocated to undergo dysplasia surveillance with AFI encountered any disadvantage by 26 
participating in this study. Last, some endoscopists performed more study colonoscopies than other 27 
possibly introducing a learning curve for AFI during the study. To minimise this learning curve during 28 
the study, participating endoscopists were required to have performed at least 20 procedures with 29 
the AFI study equipment in patients with longstanding UC prior to the start of the study. All study 30 
endoscopists also participated in a one-day teaching session and therefore we presume that this 31 
resulted in comparable scope-handling abilities and interpretation of the endoscopic images 32 
between endoscopists when using AFI. 33 
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This study can be regarded as an exemplar for the introduction of new endoscopic 1 
technology into daily clinical practice. Prior research showed AFI to be superior to WLE in dysplasia 2 
detection in a randomised order back-to-back colonoscopy study. In order to be a reasonable 3 
alternative to CE, which is currently advised in prevailing guidelines, AFI should be at least non-4 
inferior to CE. Performing such a formal non-inferiority trial would have required over 1,300 5 
participants. Therefore we decided to perform a phase II pathfinder study with predefined 6 
performance thresholds which should be reached before AFI should be further investigated in a 7 
larger non-inferiority trial. Our approach avoided the very considerable extra efforts that would have 8 
been needed to undertake such a large trial.  9 
In conclusion, in this randomised controlled trial AFI could not demonstrate predefined 10 
performance thresholds compared to CE for dysplasia detection in patients with longstanding UC. CE 11 
was superior in an exploratory post-hoc evaluation and therefore remains the preferred surveillance 12 
technique. Future work should focus on comparing CE with high-definition white light endoscopy or 13 
high-definition image-enhanced endoscopy techniques as NBI, FICE and iScan. In the meantime, 14 
strenuous efforts should be undertaken to increase the adoption of CE as preferred dysplasia 15 
surveillance method in daily clinical practice. 16 
 17 
ACKNOWLEDGEMENTS 18 
We thank Suzanne Henry (NIHR Nottingham Biomedical Research Centre, Nottingham, 19 
United Kingdom), Gayle Clifford (South Tyneside NHS Foundation Trust, Tyne and Wear, United 20 
Kingdom), Deborah Wilson (North Tees and Hartlepool NHS Foundation Trust, Stockton on Tees, 21 
United Kingdom), Tracey Johnston (North Tees and Hartlepool NHS Foundation Trust, Stockton on 22 
Tees, United Kingdom), Jean Wilson (Clinical Trials Facility, TeesTranslational Gastroenterology Unit, 23 
John Radcliffe Hospital, Oxford, United Kingdom) and Christine Cohen (Academic Medical Center, 24 
Amsterdam, the Netherlands) for their invaluable help with patient recruitment and data collection. 25 
We thank Dr. Gareth Horgan (St. Vincent’s Hospital, Dublin, Ireland) and Dr. Shivaram Bhat 26 
(Craigavon Area Hospital, Portadown, United Kingdom) for assistance with study set up. We thank 27 
Nan van Geloven (Academic Medical Center, Amsterdam, the Netherlands), professor Patrick Bossuyt 28 
(Academic Medical Center, Amsterdam, the Netherlands) and Paul Bassett (Statsconsultancy Ltd, 29 
Amersham, United Kingdom) for their invaluable help with the sample size calculation and statistical 30 
analysis.    31 
 32 
 21 
 
Table 1. Patient characteristics. 1 
 Autofluorescence 
imaging (N=105) 
Chromoendoscopy 
(N=105) 
Mean age, years (SD) 56·3 (13·1) 56·1 (12·3) 
Female, n (%) 44 (41·9%) 44 (41·9%) 
UC duration in years, median (IQR) 22·5 (15·0-32·8) 19·0 (13·0-27·3) 
Extent of colitis, n (%)   
Pancolitis (E3) 68 (64·8%) 74 (70·5%) 
Left sided (E2) 37 (35·2%) 31 (29·5%) 
Previous dysplasia detected during 
surveillance, n (%) 
16 (15·2%) 18 (17·1%) 
Concomitant diagnosis of PSC, n (%) 18 (17·1%) 20 (19·0%) 
Surveillance interval in years, median (IQR) 3·0 (1·5-4·0) 3·0 (1·0-4·0) 
Family history of CRC, n (%) 17 (16·3%) 17 (16·3%) 
Previous or current use of 
immunomodulating* therapy, n (%) 
56 (53·3%) 60 (57·1%) 
*Immunomodulating therapy is defined as methotrexate, thiopurines and biological therapy 2 
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 5 
 6 
 7 
 8 
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Table 2. Colonoscopy characteristics. 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 Autofluorescence 
imaging  
Chromoendoscopy  P-value 
(2-sided) 
Mayo 1 colitis, n (%) 25 (23·8%) 24 (22·9%) 0·87 
Post inflammatory polyps , n (%) 23 (21·9%) 22 (21·0%) 0·87 
Tubular shortened colon, n (%) 5 (4·8%) 6 (5·7%) 0·76 
BBPS, median (IQR) 8 (7-9) 8 (8-9) 0·11 
Sedation, n   0·69 
None 15 9  
Midazolam and/or fentanyl 88 90  
Propofol 2 6  
Hyoscine butylbromide, n (%) 64 (61%) 68 (65%) 0·29 
Colonoscopies per center, n    1·00 
Center 1 34  32   
Center 2 24 26   
Center 3 15 16  
Center 4 18 18  
Center 5 14 13  
Caecal intubation time in min, median 
(IQR) 
10·0 (7·0-16·6) 11·7 (8·0-17·0) 0·15 
Withdrawal time  in min, median (IQR) 18·0 (15·0-24·9) 25·1 (18·9-33·8) <0·0001 
Inspection time  in min, median (IQR) 15·2 (12·0-19·0) 16·0 (12·9-26·0) 0·15 
Time related to dye-application, bowel 
cleansing and lesion removal in min, 
median (IQR) 
3·1 (2·0-3·1) 7·0 (1·2-13·2) 0·02 
 23 
 
Table 3. Main and secondary study outcome measures. 1 
 Autofluorescence 
imaging  
Chromoendoscopy  Ratio  
(2-sided 80% CI) 
P-value 
(2-sided) 
Patient level analysis     
Dysplastic – y/n 12·4% (13/105) 19·1% (20/105) 0·65 (0·43,0·99) 0·18 
Dysplastic – N 0·13 ± 0·37 0·37 ± 1·02 0·36 (0·21,0·61) 0·01 
     
Neoplastic – y/n 15·2% (16/105) 24·8% (26/105) 0·62 (0·43, 0·89) 0·08 
Neoplastic – N 0·17 ± 0·43 0·52 ± 1·20 0·34 (0·21, 0·54) 0·002 
     
SSL – y/n 2·9% (3/105) 6·7% (7/105) 0·43 (0·18, 1·02) 0·19 
SSL – N 0·04 ± 0·24 0·13 ± 0·62 0·29 (0·10, 0·80) 0·12 
     
Targeted biopsy – y/n 41·9% (44/105) 63·8% (67/105) 0·66 (0·55, 0·78) 0·002 
Targeted biopsy – N 0·69 ± 1·07 1·39 ± 1·69 0·49 (0·41, 0·59) 0·0003 
     
Polyp level analysis     
Dysplasia yield (*) 20·0% (13/65) 26·8% (37/138) 1·13 (0·47, 2·70) (#) 0·86 
Summary statistics are: Percentage (n/N) or mean ± standard deviation. (*) Excluding obvious hyperplastic & inflammatory 2 
polyps. (#) Relative differences reported as odds ratio (80% CI) 3 
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Table 4. Characteristics of detected dysplastic lesions. 1 
 Autofluorescence 
imaging  (N=14) 
Chromoendoscopy 
(N=38) 
Location, n   
Caecum 5 2 
Ascending 6 5 
Transverse 2 15 
Descending 0 5 
Sigmoid 1 8 
Rectum 0 3 
   
Located in previous or current inflamed 
colon segment, n  
7  25 
   
Size, median (IQR) 3mm (2-4) 3mm (2-8) 
   
Morphology, n    
Sub-pedunculated (Isp) - 2 
Sessile (Is) 5 10 
Flat or flat elevated (IIa or IIb) 8 25 
Depressed (IIc) - 1 
   
Removal, n   
Biopsy 4 20 
Cold polypectomy 6 14 
Endoscopic mucosal resection 3 4 
   
Direct complete removal, n 11 27 
   
Dysplasia, n    
Low-grade dysplasia 14 36 
High-grade dysplasia 0 1 
Invasive cancer 0 1 
 2 
 3 
 4 
 5 
 6 
 7 
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Figure 1. CONSORT patient flowchart. 1 
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Figure 2. Image of 10mm flat-elevated lesion detected with AFI (1a) with corresponding narrow band 1 
imaging (1b) and white light images (1c). The lesion was lifted with submucosal methylene blue prior 2 
to endoscopic mucosal resection (1d). 3 
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